Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.34 - $6.58 $434 - $658
-100 Reduced 2.08%
4,700 $21,000
Q2 2024

Aug 14, 2024

BUY
$4.19 - $6.23 $19,274 - $28,658
4,600 Added 2300.0%
4,800 $21,000
Q1 2024

May 15, 2024

SELL
$5.69 - $8.08 $90,471 - $128,472
-15,900 Reduced 98.76%
200 $1,000
Q4 2023

Feb 14, 2024

BUY
$3.77 - $8.39 $754 - $1,678
200 Added 1.26%
16,100 $128,000
Q3 2023

Nov 14, 2023

BUY
$5.2 - $8.77 $37,960 - $64,021
7,300 Added 84.88%
15,900 $103,000
Q2 2023

Aug 14, 2023

BUY
$5.86 - $7.93 $1,758 - $2,379
300 Added 3.61%
8,600 $51,000
Q1 2023

May 15, 2023

BUY
$5.85 - $9.84 $1,170 - $1,968
200 Added 2.47%
8,300 $51,000
Q4 2022

Feb 14, 2023

BUY
$6.88 - $9.55 $55,728 - $77,355
8,100 New
8,100 $74,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $159M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.